AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer

European Journal of Endocrinology

Volumn 169, Issue 4, 2013, Pages 521-528

  Vidal, Ana Paula ^a   Andrade, Bruno M ^a   Vaisman, Fernanda ^a,b   Cazarin, Juliana ^a   Pinto, Luis Felipe Ribeiro ^b   Breitenbach, Marisa Maria Dreyer ^b   Corbo, Rossana ^a,b   Caroli Bottino, Adriana ^a   Soares, Fernando ^c   Vaisman, Mario ^a   Carvalho, Denise P ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ARTICLE; CANCER CELL; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; THYROID ADENOMA; THYROID CARCINOMA; THYROID MICROCARCINOMA; TISSUE MICROARRAY; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMP-ACTIVATED PROTEIN KINASES; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHORYLATION; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS; UP-REGULATION; YOUNG ADULT;

EID: 84884824918     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0284     Document Type: Article

References (31)

1. Dandapani M & Hardie DG. AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells? Biochemical Society Transactions 2013 41 687-693. (doi:10.1042/BST201 20351)
2. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes and Development 2011 25 1895-1908. (doi:10.1101/gad.17420111)
3. Andrade BM, Araujo RL, Perry RL, Souza EC, Cazarin JM, Carvalho DP & Ceddia RB. A novel role for AMP-kinase in the regulation of the NaC/IK-symporter and iodide uptake in the rat thyroid gland. American Journal of Physiology. Cell Physiology 2011 300 C1291-C1297. (doi:10.1152/ajpcell.00136.2010)
4. Gaidhu MP & Ceddia RB. Remodeling glucose and lipid metabolism through AMPK activation: relevance for treating obesity and type 2 diabetes. Clinical Lipidology 2009 4 465-477. (doi:10.2217/clp. 09.30)
5. Kahn BB, Alquier T, Carling D & Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 2005 1 15-25. (doi:10.1016/j.cmet.2004.12.003) (Pubitemid 43960587)
6. Andrade BM, Cazarin J, Zancan P & Carvalho DP. AMP-activated protein kinase upregulates glucose uptake in thyroid PCCL3 cells independent of thyrotropin. Thyroid 2012 22 1063-1068. (doi:10.1089/thy.2012.0041)
7. Rattan R, Giri S, Singh AK & Singh I. 5-Aminoimidazole-4-carboxamide- 1-b-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. Journal of Biological Chemistry 2005 280 39582-39593. (doi:10.1074/jbc. M507443200) (Pubitemid 41713917)
8. Luo Z, Zang M & Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncology 2010 6 457-470. (doi:10.2217/fon.09.174)
9. Shackelford DB & Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumor suppression. Nature Reviews. Cancer 2009 9 563-575. (doi:10.1038/nrc2676)
10. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ & Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Molecular Cell 2005 18 283-293. (doi:10.1016/j.molcel.2005.03.027) (Pubitemid 41350534)
11. Grisouard J, Dembinski K, Mayer D, Keller U, Mu ller B & Christ-Crain M. Targeting AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with insulin resistance and breast cancer cell proliferation. Diabetology & Metabolic Syndrome 2011 20 3-16. (doi:10.1186/1758-5996-3-16)
12. Hadad SM, Baker L,Quinlan PR,Robertson KE, Bray SE, ThomsonG, Kellock D, Jordan LB, Purdie CA, Hardie DG et al. Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 2009 9 307. (doi:10.1186/1471- 2407-9-307)
13. Gallagher EJ & LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Annals of the New York Academy of Sciences 2011 1243 54-68. (doi:10.1111/j.1749-6632.2011.06285.x)
14. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL & Thompson CB. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid b-oxidation. Oncogene 2005 24 4165-4173. (doi:10.1038/sj.onc.1208622) (Pubitemid 40961771)
15. Hayashi T, Hirshman MF, Fujii N, Habinowski SA, Witters LA & Goodyear LJ. Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism. Diabetes 2000 49 527-531. (doi:10.2337/diabetes. 49.4.527) (Pubitemid 30183739)
16. Schlumberger M. Papillary and follicular thyroid carcinoma. New England Journal of Medicine 2000 338 297-306. (doi:10.1056/NEJM199801293380506)
17. Mazzaferri EL & Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocrine-Related Cancer 2002 9 227-247. (doi:10.1677/erc.0. 0090227) (Pubitemid 36240764)
18. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167-1214. (doi:10.1089/thy.2009. 0110)
19. Goretzki PE, Simon D, Frilling A,Witte J, Reiners C, Grussendorf M, Horster FA & Roher HD. Surgical reintervention for differentiated thyroid carcinoma. British Journal of Surgery 1994 80 1009-1012. (doi:10.1002/bjs. 1800800826)
20. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Seminars in Surgical Oncology 1999 16 34-41. (doi:10.1002/(SICI)1098-2388(199901/02)16:1!34:: AID-SSU7O3.0.CO;2-2)
21. Coelho SM, Corbo R, Buescu A, Carvalho DP & Vaisman M. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. Journal of Endocrinological Investigation 2004 27 334-339. (Pubitemid 38750135)
22. De Lellis AR, Lloyd RV, Heitz PU & Eng C. Thyroid and parathyroid tumors. In Pathology and Genetics of Tumors of Endocrine Organs. World Health Organization Classification of Tumors, 1st edn, pp 49-133. Eds AR De Lellis & EDWilliams. Lyon: WHO, IARC, 2004.
23. Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K & Walker R. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. Journal of Clinical Pathology 2000 53 634-635. (doi:10.1136/jcp.53.8.634) (Pubitemid 30640178)
24. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M & Robbins RJ. Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001 12 1169-1175. (doi:10.1089/10507250152741028) (Pubitemid 34041898)
25. Faustino A, Couto JP, Populo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simoes M & Soares P. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2012 97 E1139-E1149. (doi:10.1210/jc.2011-2748)
26. Inoki K, Kim J & Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annual Review of Pharmacology and Toxicology 2012 10 381-400. (doi:10.1146/annurev-pharmtox-010611-134537)
27. Esteve-Puig R, Canals F, Colome N, Merlino G & Recio JA. Uncoupling of the LKB1-AMPKa energy sensor pathway by growth factors and oncogenic BRAF. PLoS ONE 2009 4 e4771. (doi:10.1371/journal.pone.0004771)
28. de Souza EC, Padron AS, Braga WM, de Andrade BM, Vaisman M, Nasciutti LE, Ferreira AC & de Carvalho DP. MTOR downregulates iodide uptake in thyrocytes. Journal of Endocrinology 2010 206 113-120. (doi:10.1677/JOE-09-0436)
29. Souza EC, Ferreira AC & Carvalho DP. The mTOR protein as a target in thyroid cancer. Expert Opinion on Therapeutic Targets 2011 15 1099-10112. (doi:10.1517/14728222.2011.594044)
30. Schmid KW & Farid NR. How to define follicular thyroid carcinoma? Virchows Archiv 2006 448 385-393. (doi:10.1007/s00428-006-0162-0)
31. Salt I, Celler JW, Hawley SA, Prescott A, Woods A, Carling D & HardieDG.AMP-activated protein kinase: greaterAMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochemical Journal 1998 334 177-187 (Pubitemid 28420987)